Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic impact of circulating plasma cells in patients with multiple myeloma, implications for plasma cell leukemia definition

  • Granell, Miquel|||0000-0002-0366-3673
  • Calvo, Xavier|||0000-0001-7934-9130
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Martínez, Clara Mª
  • Teixidó, Montserrat
  • Gimenez, Mª Teresa
  • Senín, Alicia
  • Sanz, Patricia
  • Campoy, Desirée
  • Vicent, Ana
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Sierra, Jorge|||0000-0002-7966-0356
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Fernandez de Larrea Rodriguez, Carlos
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×10 9 /L vs. 214×10 9 /L, P <0.0001) and higher bone marrow plasma cells (median 53% vs. 36%, P =0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.